NATCO Pharma Limited has announced the closure of its Rights Issue, which opened on October 12, 2026, and concluded on October 22, 2026. The issue was approved by the Board of Directors on September 25, 2026, aiming to raise an aggregate amount of up to ₹12,794 million by issuing equity shares at a price of ₹750/- per share.
NATCO Pharma Rights Issue Concludes
NATCO Pharma Limited has officially announced the closure of its recent Rights Issue. The issue, which was aimed at raising substantial capital for the company, commenced on Monday, October 12, 2026, and successfully closed on Thursday, October 22, 2026.
Issue Details and Approval
The decision to proceed with the Rights Issue was made during a meeting of the Board of Directors held on September 25, 2026. The approved terms included the issuance of equity shares, each with a face value of Rs.2/-, at a price of Rs.750/- per share. This initiative was designed to raise an aggregate amount of up to Rs.12,794 million, in compliance with the Companies Act, 2013, and other relevant securities regulations.
NATCO Pharma Limited is a significant player in the pharmaceutical sector, and this capital raise is expected to support its future growth initiatives and operational expansion. The company has ensured adherence to all applicable laws and regulations throughout the issuance process.
Source: BSE
